Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

Paolo Maggi1, Giuseppe Vittorio De Socio2, Barbara Menzaghi3, Chiara Molteni4, Nicola Squillace5, Lucia Taramasso6, Marta Guastavigna7, Giulia Gamboni2, Giordano Madeddu8, Francesca Vichi9, Antonio Cascio10, Eleonora Sarchi11, Giovanni Pellicano12, Canio Vito Martinelli13, Benedetto Maurizio Celesia14, Laura Valsecchi15, Roberto Gulminetti16, Giovanni Cenderello17, Andrea Parisini18, Leonardo Calza19, Katia Falasca20, Giancarlo Orofino7, Elena Ricci21*, Antonio Di Biagio6 and Paolo Bonfanti5

Abstract

Background: In persons living with HIV (PLWH), the burden of non-communicable chronic diseases increased over time, because of aging associated with chronic inflammation, systemic immune activation, and long-term exposure to the combination antiretroviral therapy (ART).

Methods: To explore the association of chronological age, age at first ART, and exposure to ART with non-communicable chronic diseases, we performed a cross-sectional analysis to evaluate the prevalence of comorbidities in patients enrolled in the SCOLTA Project, stratified by groups of chronological age (50–59 and 60–69 years) and by years of antiretroviral treatment (ART, ≤ 3 or > 3 years).

Results: In 1394 subjects (23.8% women), mean age at enrollment was 57.4 (SD 6.5) years, and at first ART 45.3 (SD 10.7). Men were older than women both at enrollment (57.6 vs 56.8, p = 0.06) and at first ART (45.8 vs 43.6, p = 0.0009). ART duration was longer in women (13.1 vs 11.7 years, p = 0.01). The age- and sex-adjusted rate ratios (aRRs, and 95% confidence interval, CI) showed that longer ART exposure was associated with dyslipidemia (aRR 1.35, 95% CI 1.20–1.52), hypertension (aRR 1.52, 95% CI 1.22–1.89), liver disease (aRR 1.78, 95% CI 1.32–2.41), osteopenia/osteoporosis (aRR 2.88, 95% CI 1.65–5.03) and multimorbidity (aRR 1.36, 95% CI 1.21–1.54). These findings were confirmed in strata of age, adjusting for sex.

Conclusions: Our data suggest that longer ART exposure was associated with increased risk of dyslipidemia, hypertension, and osteopenia/osteoporosis, hence the presence of multimorbidity, possibly due to the exposition to more toxic antiretrovirals. We observed different comorbidities, according to ART exposure and age.

Keywords: HIV, Multimorbidity, ART exposure, Age

Background

In recent years, the prevention and the early treatment of co-morbidities among persons living with HIV infection (PLWH) has become a major issue in the management of these patients. In fact, a number of non-communicable diseases (cardiovascular [1], renal [2], neurocognitive [3, 4], bone disease [5], non-AIDS related cancers [6]) are
more frequently observed among PLWH with respect to the general population as a consequence of aging, higher exposure to behavioral factors (such as smoking, substance abuse and concurrent sexually transmitted diseases), chronic inflammation, systemic immune activation, and long-term exposure to the combination antiretroviral therapy (ART) [7–9]. Moreover, the presence of multiple chronic co-morbidities and co-medication [10], could determine further difficulties in their management.

Aimed at the purpose of defining the possible different profiles in terms of type and quantity of non-communicable diseases among PLWH, we described the distribution of comorbidities according to their chronological age, and the length of exposition to ART.

Methods
This was a cross-sectional analysis of baseline data from the Surveillance COHort Long-Term Toxicity of Antiretrovirals/antivirals (SCOLTA) project, an ongoing prospective cohort study [11]. Briefly, subjects were enrolled if they were aged 18 years or more, in need of initiating a cohort drug and gave their informed consent to participate into the study, which was approved by the institutional ethics committee of the coordinating center in 2002 and amended in 2013 and 2019. At enrollment, information on type and duration of previous ART were collected, as well as on diagnosed comorbidities. All new patients in SCOLTA are systematically screened for comorbidities and, in the follow up, all non-communicable diseases of new insurance are registered.

Included comorbidities (diagnosed with laboratory, clinical or instrumental data and/or drug tracing criteria) were diabetes mellitus; hypertension; previous cardiovascular diseases, defined as diagnosed atherosclerosis, carotid plaques, hypertensive cardiomyopathy, ischemic cardiopathy, atrial fibrillation, cardiac hypertrophy, tachycardia, and history of brain hemorrhage, acute myocardial infarction, transitory ischemic attack, or cardiac failure; dyslipidemia, based on serum cholesterol (>200 mg/dL) and triglycerides (>150 mg/dL) values; renal impairment (diagnosis of chronic kidney disease or estimated glomerular filtration (eGFR) < 60 mL/min, according to the Modification of Diet in Renal Disease formula); central nervous system (CNS) disturbance, based on medical history of anxiety, depression, psychosis; liver disease, such as any chronic hepatitis or detectable hepatitis C virus (HCV) RNA; osteopenia/osteoporosis, based on bone density scan and drug-tracing criteria; epilepsy, based on specialist’s diagnosis; lung disease (asthma, chronic obstructive pulmonary disease, emphysema) based on specialist’s diagnosis; hypovitaminosis D; history of non-AIDS defining cancers, based on medical history and oncologic follow up; obesity, defined as body mass index > 30.0 kg/m². Multi-morbidity was defined as the presence of two or more co-morbidities other than HIV infection.

To focus on older subjects, we selected participants enrolled since 2013 and aged 50 or more years at study entry. To investigate the effect of ART exposure, we compared PLWH with low exposure (naïve or up to 3 years of treatment) and PLWH with moderate-high exposure (more than 3 years).

Continuous variables were described as means (and standard deviation, SD) if normally distributed, and as medians (and interquartile range, IQR) if not normally distributed. They were compared using parametric and non-parametric tests, respectively. Categorical variables were described as frequency (and percentage, %) and their distribution was compared using the Chi-square test (or Fisher exact test, as appropriate).

Using unconditional multiple logistic regression, we estimated the rate ratios (RRs) and the corresponding 95% confidence intervals (CIs) for diabetes, hypertension, other cardiovascular diseases (CVDs), dyslipidemia, chronic kidney disease (CKD), CNS disturbance, bone loss (osteopenia and osteoporosis), non-AIDS-related malignancies and multimorbidity in categories of ART duration (>3 years vs ≤3 years). To account for potential confounders, we included terms for age, sex at birth (as factors related to most chronic comorbidities) and HCV coinfection (except for liver disease since HIV coinfection is classified as such). All the analyses were performed with the SAS software, version 9.4 (SAS Institute, Inc., Cary, NC, USA).

Results
Out of 3040 patients enrolled since 2013, we excluded 1646 (54.1%) who were younger than 50 years at study entry. One thousand three hundred and ninety-four were eligible for this analysis, 984 (70.6%) aged 50–59 years and 410 (29.4%) aged 60 years or more.

Mean age was 57.4 (SD 6.5) years at study entry, and 45.3 (SD 10.7) years at first ART. Both were higher in men than in women (57.6 vs 56.8, p = 0.06, and 45.8 vs 43.6, p = 0.0009). On the contrary, ART duration was longer in women (13.1 vs 11.7 years, p = 0.01).

Baseline patients’ characteristics are reported in Table 1, by ART exposure. Groups were different in term of HCV positivity, risk factor for HIV acquisition, median CD4+ cell count (lower in low ART exposure), and mean eGFR (higher in low ART exposure). One hundred and sixty-eight (12.0%) patients did not present any comorbidities.

We found a significantly higher frequency of dyslipidemia, hypertension, hypovitaminosis D, chronic liver
disease, osteopenia/osteoporosis, epilepsy and multimorbidity in PLWH with longer ART exposure (Table 2). After accounting for age class (50–59 and ≥ 60 years), sex and HCV coinfection (except for liver disease), all associations but epilepsy were confirmed.

Sex, age class (50–59, ≥ 60 years), and HCV coinfection (except for liver disease) were included in the multivariable model.

Prevalence of comorbidities by age class (50–59 and ≥ 60 years) are shown in Fig. 1.

In the multivariate model, the findings were similar to those from the overall analysis, with prevalence of dyslipidemia, hypertension, hypovitaminosis D, osteopenia/osteoporosis and multimorbidity significantly higher in the ART exposed subjects (Table 3). However, we noted that higher exposure to ART was associated with CVD in PLWH aged 50–59, but not in those aged ≥ 60.

Sex and HCV coinfection (except for liver disease) were included in the multivariate model.

In 2019, we started to collect information on CD4+ nadir. This data was available for about one-third of patients, equally distributed between groups on ART treatment duration. Including this variable in the model, the RRs were similar to those calculated without it (Tables 2, 3), although the confidence intervals were wider because of the lower sample size.

### Discussion

In this analysis of baseline data from the SCOLTA cohort study, we found that ART exposure is significantly associated with dyslipidemia, hypertension, and osteopenia/osteoporosis, hence with the presence of multimorbidity. On the contrary, diabetes, CVD, renal impairment, CNS disorders and non-AIDS-related malignancies were not associated with longer ART exposure. These results were confirmed in strata of age.

In the 50–59 group, longer ART duration was associated with increased risk of CVD, dyslipidemia and
Table 2  Comorbidities by ART exposure: prevalence and adjusted rate ratios (aRR) for morbidity risk (reference category ≤ 3 years)

| Comorbidity                  | Total                     | ART exposure       | > 3 vs ≤ 3 years | aRR   | 95% CI       |
|------------------------------|---------------------------|--------------------|------------------|-------|--------------|
|                              | N    | %    | N    | %    | N    | %    | P     |       |
| Dyslipidemia                 | 909  | 65.2 | 169  | 52.3 | 740  | 69.1 | <0.0001 | 1.35  | 1.20–1.52 |
| Hypertension                 | 440  | 31.6 | 73   | 22.6 | 367  | 34.3 | <0.0001 | 1.52  | 1.22–1.89 |
| Hypovitaminosis D            | 342  | 24.5 | 46   | 14.2 | 296  | 17.6 | <0.0001 | 1.86  | 1.40–2.49 |
| Liver disease                | 285  | 20.4 | 42   | 13.0 | 243  | 22.7 | 0.0002  | 1.78  | 1.32–2.41 |
| CNS disturbance              | 201  | 14.4 | 52   | 16.1 | 149  | 13.9 | 0.33    | 0.78  | 0.56–1.05 |
| Renal impairment             | 152  | 10.9 | 28   | 8.7  | 124  | 11.6 | 0.14    | 1.39  | 0.92–2.09 |
| Osteopenia/osteoporosis      | 148  | 10.6 | 13   | 4.0  | 135  | 12.6 | <0.0001 | 2.88  | 1.65–5.03 |
| Diabetes                     | 124  | 8.9  | 29   | 9.0  | 95   | 8.9  | 0.95    | 1.06  | 0.70–1.60 |
| Other CVD                    | 114  | 8.2  | 19   | 5.9  | 95   | 8.9  | 0.09    | 1.40  | 0.87–2.26 |
| Obesity                      | 110  | 7.8  | 19   | 5.9  | 91   | 8.5  | 0.13    | 1.48  | 0.91–2.40 |
| Epilepsy                     | 57   | 4.1  | 6    | 1.9  | 51   | 4.8  | 0.02    | 2.06  | 0.88–4.82 |
| Non-AIDS-related malignancies| 49   | 3.5  | 9    | 2.8  | 40   | 3.7  | 0.42    | 1.25  | 0.61–2.59 |
| Lung disease                 | 37   | 2.6  | 9    | 2.8  | 28   | 2.6  | 0.87    | 0.91  | 0.43–1.90 |
| Multimorbidity               | 852  | 61.1 | 153  | 47.4 | 699  | 65.3 | <0.0001 | 1.36  | 1.21–1.54 |

ART antiretroviral treatment, CI confidence interval, CNS central nervous system, CVD cardiovascular disease, aRR adjusted rate ratio

Fig. 1  Prevalence of morbidities and multimorbidity, by age class and antiretroviral therapy (ART) exposure
osteopenia/osteoporosis and, in general, of multimorbidity, but not of CNS disturbance and malignancies.

The higher number of over-sixties with dyslipidemia, hypertension, hypovitaminosis D and osteopenia/osteoporosis could be the effect of the exposure to more toxic antiretrovirals, like abacavir, protease inhibitors and tenofovir disoproxil fumarate. The relation of multimorbidity in geriatric HIV positive patients with a longer duration of HIV-infection and/or ART exposure can at least partially be attributed to the metabolic toxicities of ART, according to Guaraldi et al. [12].

On the contrary, the prevalence of CVD in older patients was similar among those with lower ART exposure, which presumably means a more recent diagnosis, maybe reflecting the fact that people with long-term exposure both to HIV and ART died prematurely.

In a recent issue of the FUNCFRAIL study [13], 801 PLWH were stratified by chronological age (50–54, 55–64 years, and > 65) and by the year of HIV diagnosis (before 1996 and after 1996). Among patients diagnosed before 1996, the authors found an increased burden of comorbidities and a higher prevalence of chronic obstructive pulmonary disease (COPD), history of cancer, osteoarthritis, depression, and other psychiatric disorders, but no differences regarding frailty and physical function; the prevalence of frailty and poor physical function was significantly higher among patients aged 65 years or more. Among patients aged ≥ 65 years, the most prevalent comorbidities were hypertension, diabetes, dyslipidemia, current cancer, and osteoarthritis. Despite the relevant difference between the results of the two studies, in the SCOLTA cohorts the two profiles of PLWH significantly differed in terms of comorbidities, as also was observed in the FUNCFRAIL study.

As regards the frequency of two or more concurrent medical conditions and their clusterization, data are scarce and difficult to compare, at least partly because of heterogeneous definitions of multi-morbidity [14, 15]. However, our findings are largely consistent with the results of other studies [10, 16, 17].

In Italy, comorbidity prevalence has been evaluated by Guaraldi et al. [16] in a sample of 2854 PLWH: using similar diagnostic criteria, previous CVD event and renal impairment prevalence estimates were largely similar, but we found a slightly lower proportion of subjects with diabetes (8.9% versus 11.1%) and a much higher proportion of hypertensive patients (31.6% versus 22.2%). In both studies age was the main determinant of multimorbidity, although in our sample male sex did not emerge as a risk factor for multimorbidity. However, in our sample the role of sex on different comorbidities was significant but not consistent throughout types: for example, women were at lower risk of liver disease and diabetes, but at higher risk for CNS disturbance and osteoporosis, thus resulting in an overall indifferent risk of multimorbidity.

In a previous study of our group [10], we found that multimorbid patients were about 54% and duration of ART was linked to higher probability of having 2 or more

### Table 3 Comorbidities by ART exposure, in strata of age

| Comorbidity                  | Prevalence by ART exposure in strata of age |  |  |  |  |
|------------------------------|--------------------------------------------|---|---|---|---|
|                              | 50–59                                      | ≥ 60 |  |  |  |
|                              | ≤ 3 years                                  | > 3 years | aRR | 95% CI | ≤ 3 years | > 3 years | aRR | 95% CI |
| N                            | 227                                       | 757 |  |  | 96 | 314 |  |  |  |
| Dyslipidemia                 | 49.8                                       | 68.1 | 1.40 | 1.22–1.62 | 58.3 | 71.3 | 1.26 | 1.05–1.52 |
| Hypertension                 | 16.7                                       | 27.2 | 1.61 | 1.16–2.23 | 36.5 | 51.3 | 1.48 | 1.10–1.99 |
| Hypovitaminosis D            | 14.5                                       | 27.7 | 1.77 | 1.25–2.50 | 13.5 | 27.4 | 2.14 | 1.26–3.64 |
| Liver disease                | 13.7                                       | 26.4 | 1.97 | 1.39–2.79 | 11.5 | 13.7 | 1.20 | 0.65–2.23 |
| CNS disturbance              | 15.4                                       | 14.5 | 0.84 | 0.58–1.21 | 17.7 | 12.4 | 0.64 | 0.37–1.11 |
| Renal impairment             | 5.3                                        | 8.6  | 1.48 | 0.81–2.73 | 16.7 | 18.8 | 1.30 | 0.74–2.28 |
| Osteopenia/osteoporosis      | 4.8                                        | 11.1 | 2.02 | 1.09–3.74 | 2.1  | 16.2 | 7.54 | 1.87–30.37 |
| Diabetes                     | 7.9                                        | 6.8  | 0.91 | 0.52–1.58 | 11.5 | 13.7 | 1.28 | 0.69–2.38 |
| Other CVD                    | 1.8                                        | 6.6  | 2.93 | 1.06–8.13 | 15.6 | 14.3 | 1.02 | 0.60–1.73 |
| Obesity                      | 7.0                                        | 8.6  | 1.25 | 0.73–2.14 | 3.1  | 8.3  | 2.72 | 0.84–8.79 |
| Epilepsy                     | 2.2                                        | 4.8  | 1.68 | 0.46–4.30 | 1.0  | 4.8  | 4.24 | 0.56–32.00 |
| Non-AIDS-related malignancies| 2.6                                        | 3.3  | 1.17 | 0.48–2.89 | 3.1  | 4.8  | 1.42 | 0.41–4.88 |
| Lung disease                 | 1.8                                        | 2.2  | 0.71 | 0.24–2.10 | 5.2  | 3.5  | 0.68 | 0.24–1.94 |
| Multimorbidity               | 43.2                                       | 62.1 | 1.41 | 1.19–1.65 | 57.3 | 72.9 | 1.30 | 1.08–1.57 |

**ART** antiretroviral treatment, **CI** confidence interval, **CNS** central nervous system, **CVD** cardiovascular disease, **aRR** adjusted rate ratio
co-morbidities. The lower proportion of multimorbidity was likely due to the younger age of enrolled subjects.

In a cross-sectional study comparing 208 HIV positive subjects with 208 matched HIV negative controls [17], the frequency of multi-morbidity was higher in the former (63% vs 43%) than in the latter, and associated with duration of HIV and ART. In our sample, multimorbidity patients were in a similar proportion, as expected since the age selection was similar.

Another interesting aspect was a comparison with the general Italian population, where the information was available [18]. An overall comparison was not feasible, since the age distribution of our patients was remarkably different. However, where information was provided in age class, we could compare some specific diseases (Additional file 1: Table S1).

For example, in a survey conducted in 2010, an overall 1.7% of men and 12.0% of women were reported as suffering from osteoporosis. Limiting the information to age classes comparable with ours, men aged 54–59, 60–64 and 65–74 years had a prevalence of osteoporosis of 2.2%, 1.7%, and 4.5%, respectively, versus 7.6%, 9.4% and 12.8% in our sample. On the contrary, in the same age classes the presence of osteoporosis in women was 18.0%, 21.2%, and 31.9% in the general Italian population, and 17.0%, 18.0% and 30.6% among women living with HIV. Similarly, CNS disturbance and hypertension were more frequent both in men and women from SCOLTA study than in the general population. Diabetes prevalence was comparable in both sexes.

In brief, comparing our data with those obtained from the general population, we can observe that, in the classes of age considered, over-fifties males are more affected by osteopenia/osteoporosis and, if over-sixties, also by high blood pressure and CNS disturbances. On the other hand, women living with HIV were more similar to the general population; this could be due to the success, in our outpatient facilities, of early diagnosis and therapeutic approaches.

In conclusion, HIV outpatient facilities nowadays provide, in our country, an opportunity for a 360 degrees assessment of comorbidities. Consequently, PLWH adherent to their schedule could be better followed for non-communicable diseases with respect to the general population. This represents a real achievement of the last decades for these patients that should be preserved, even though, unfortunately, the Covid19 pandemic and the post-Covid19 era could seriously jeopardize this advantage. In the screening of non-communicable diseases, PLWH over-fifties present different risk profiles for comorbidities, according to their ART exposure, and should not be considered as a uniform group. Distinguishing them according to different profiles may contribute to the design of different diagnostic and therapeutic approaches.

**Abbreviations**

AIDS: Acquired immunodeficiency syndrome; aRR: Adjusted rate ratio; ART: Antiretroviral therapy; BMI: Body mass index; CDC: Center for Diseases Control; CI: Confidence interval; CISAI: Coordinamento Italiano per lo Studio di Allergia e Infezioni da HIV; CVD: Cardiovascular diseases; eGFR: Estimated glomerular filtration rate; HCV Ab+: Antibodies for hepatitis C virus; HIV: Human Immunodeficiency Virus; INSTI: Integrase strand transfer inhibitors; IDU: Intravenous
drug use; IQR: Interquartile range; NNRTI: Non nucleoside reverse transcriptase inhibitors; RR: Rate ratio; PI: Protease inhibitors; PLWH: Persons living with HIV; SD: Standard deviation.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12879-022-07739-y.

**Additional file 1:** Table S1. Comorbidity by age class (%), comparison with the general Italian population.

**Acknowledgements**

We want to acknowledge all the members of Coordinamento Italiano Studio Allergie e Infeczione dal HIV (CISA). Coordinators: Paolo Bonfanti (Monza), Antonio Di Biagio (Genova). Data Management and Analysis: Elena Recchi (Milano). Health Informatic Service: L.D. Magnoni, M. Bonetto (Genova, Healthcomly); M. Giacomini (Genova, DIBIRS). Participating centers: E. Sarchi, G. Chichino, C. Bolla (Alessandria); A. Saracino, D. Fiordelisi (Bari); L. Calza (Bologna); B. Menzaghi, M. Farinazzo, F. Franzetti (Busto Arsizio); G. Angioni (Cagliari); P. Maggi, F. Simeone, A. Maselli (Caserta); G. Bruno, B. M. Celesia (Catania); C. Grosso (CESena); K. Falasca (Chieti); L. Pusterla, G. Chieffo (Corno); A. Mastromai, G. Guardagnino (Cosenza); F. Franzetti, S. Rusconi (Legnano); S. Carradon (Ferrara); F. Vichi, E. Salomoni (Firenze); C.V. Martinelli, F. Lagi (Firenze); A. Di Biagio, C. Dentone, L. Taramasso, M. Brossini (Genova); E. Pontalli, A. Parisini, F. Del Puente (Genova); C. Moltene, A. Pandolfino, S. Piconi (Lecco); S. Rusconi, M. Franzetti (Legnano); G. F. Pellicano, G. Nunnari (Messina); L. Valsecchi, L. Corderi, S. Parisini, G. Rizzardini (Milano); F. Conti (Milano); A. Bandera, A. Gori (Milano); D. Motta, M. Merli, M. Puoti (Milano); P. Bonfanti, N. Squillace, M. Rossi, E. Pollastri, N. Corti (Monza); S. Martini (Napoli); O. Bangicchi, P.L. Garaveli (Novara); A. Cappio, M. Trizzino (Palermo); R. Galmi-netti, L. Pagnucco (Pavia); G. V. De Socio, G. Gamboni, D. Altobelli, D. Francisci (Perugia); E. Mazzotta, G. Parruti (Pescara); S. Cicalini, R. Bellagamba, A. Antinori (Pom); M. Morelli (Humanitas); G. Gendreloro (Sanremo); G. Maddeddu, M. S. Mameli (Sassari); G. Orofino, M. Guastavina (Torino); A. Londero, A. Giacinta, C. Tuscini (Udine); G. Battagin, V. Manfrin (Vicenza).

**Author contributions**

Conceptualization: PM, PB, GVDS and ADB; Methodology: PM, GVDS and EDR; Investigation and data curation: BM, CM, NS, LT, MG, GG, GM, FV, AC, ES, GP, O. Bargiacchi, P. L. Garavelli (Novara); A. Cascio, M. Trizzino (Palermo); R. Gulmini, L. Pagnucco (Pavia); G. V. De Socio, G. Gamboni, D. Altobelli, D. Francisci (Perugia); E. Mazzotta, G. Parruti (Pescara); S. Cicalini, R. Bellagamba, A. Antinori (Pom); M. Morelli (Humanitas); G. Gendreloro (Sanremo); G. Maddeddu, M. S. Mameli (Sassari); G. Orofino, M. Guastavina (Torino); A. Londero, A. Giacinta, C. Tuscini (Udine); G. Battagin, V. Manfrin (Vicenza).

**Funding**

No funding was obtained for this study.

**Availability of data and materials**

The datasets analyzed during the current study are not publicly available due to restrictions imposed by the Ethics Committees but are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate.** The SCOLTA Project was conducted in accordance with the Declaration of Helsinki. It was approved by Comitato Etico Locale L Sacco Hospital, Milano, Italy, on September 18th, 2002, amended on June 12th, 2013 (protocol no. 352/2013), on December 20th, 2019 (Protocol no. 54085/2019) and on March 3rd, 2020 (Protocol no. 2020/EM/029). All patients included gave their written informed consent to participate in the study.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they do not have any competing interests.

**Author details**

1 Department of Infectious Disease, University of Campania Luigi Vanvitelli, Naples, Italy. 2 Clinic of Infectious Diseases, Department of Medicine 2, Azienda OSPedaliera di Perugia, Santa Maria Hospital, Perugia, Italy. 3 Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio Hospital, Busto Arsizio, Italy. 4 Infectious Disease Unit, Ospeodale A. Manzoni, Lecco, Italy. 5 Infectious Diseases Clinic, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy. 6 Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa, Italy. 7 Unit of Infectious Diseases, “Divisione A”; Amedeo di Savoia Hospital, Turin, Italy. 8 Unit of Infectious and Tropical Diseases, Department of Medical and Experimental Sciences, University of Sassari, Sassari, Italy. 9 Infectuous Diseases Department, SOC 1, USLCENTRO Firenze, Santa Maria Annunziata Hospital, Florence, Italy. 10 Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy. 11 Infectious Diseases Unit, SS. Antonio e Biagio e Cesare Arigo Hospital, Alessandria, Italy. 12 Unit of Infectious Diseases, Department of Human Pathology of the Adult and the Developmental Age “G. Barresi”, University of Messina, Messina, Italy. 13 ISDD Malattie Infettive e Tropicali AOU Careggi, Firenze, Italy. 14 Unit of Infectious Diseases, University of Catania, ARNAS Garibaldi, Catania, Italy. 15 Infectious Disease Unit, ASST Fatebenefratelli Sacco, Milan, Italy. 16 Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy. 17 Infectious Disease Department, Sanremo Hospital, Sanremo, Italy. 18 Department of Infectious Diseases, Galliera Hospital, Genoa, Italy. 19 Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy. 20 Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University ‘G. d’Annunzio’ Chieti-Pescara, Chieti, Italy. 21 Fondazione ASIA Onlus, via Garibaldi, 13, 20090 Buccinasco, MI, Italy.

Received: 7 April 2022 Accepted: 15 September 2022 Published online: 23 September 2022

**References**

1. Maggi P, Di Biagio A, Rusconi S, Cicalini S, D’Abbraccio M, d’Ettorre G, et al. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis. 2017;17:551.

2. Rasch MG, Engsig FN, Feldt-Rasmussen B, Kirk O, Kronborg G, Pedersen C, et al. Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study. Scand J Infect Dis. 2012;44:689–96.

3. Madsen LW, Fabricius T, Hjmeld S, Hansen TM, Møssner BK, Birkeromse I, et al. Depressive symptoms are frequent among drug users, but not associated with hepatitis C infection. Scand J Infect Dis. 2014;46:566–72.

4. van den Dries LWJ, Wagener MN, Jiskoot LC, Visser M, Robertson KR, Adriani KS, van Gorp ECM. Neurocognitive impairment in a chronically well suppressed HIV-infected population: the Dutch TREVI cohort study. AIDS Patient Care STDs. 2017;31:529–34.

5. Kruger MJ, Neil TA. Bone mineral density in people living with HIV: a narrative review of the literature. AIDS Res Ther. 2017;14:35.

6. J.X. Lu H. Malignancies in HIV-infected and AIDS patients. Adv Exp Med Biol. 2017;1018:167–79.

7. Krentz HB, Kliever G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in southern Alberta, Canada, from 1984 to 2003. HIV Med. 2005;6:99–106.

8. Grinztejn B, Luz PW, Pacheco AG, Santos DV, Velasque J, Moreira RI, et al. Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era. PLoS ONE. 2013;8: e59768.

9. Ford N, Shubber Z, Meintjes G, Grinztejn B, Eholie S, Mills EJ, et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. Lancet HIV. 2015;2:e438–44.

10. Maggi P, Santoro CR, Nofti M, et al. Clusterization of co-morbidities and multimorbidities among persons living with HIV: a cross-sectional study. BMC Inf Dis. 2019;19:551.

11. Bonfanti P, Martinelli C, Ricci E, et al. CISA Group (Italian Coordinators for the Study of Allergies HIV/Infection): An Italian approach to post marketing monitoring: preliminary results from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2005;39:317–20.
12. Guaraldi G, Malagoli A, Calcagno A, Mussi C, Celesia BM, Carli F, Piconi S, De Socio GV, Cattelan AM, Orefino G, Riva A, Focà E, Nozza S, Di Perri G. The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65–74 years and more than 75 years. BMC Geriatr. 2018;18(1):99. https://doi.org/10.1186/s12877-018-0789-0.

13. Branas F, Galindo MJ, Torralba M, et al, FUNCRAIL Study Group. Long-term HIV survivors and adults 65 or over with HIV: two separate profiles with different needs. 18th European AIDS Conference PI 17/00859.

14. Fortin M, Stewart M, Poitras ME, Almirall J, Maddocks H. A systematic review of prevalence studies on multi-morbidity: toward a more uniform methodology. Ann Fam Med. 2012;10:142–51.

15. Valderas J, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009;7:357–63.

16. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120–6.

17. Maciel RA, Klück HM, Durand M, Sprinz E. Comorbidity is more common and occurs earlier in persons living with HIV than in HIV-uninfected matched controls, aged 50 years and older: a cross-sectional study. Int J Infect Dis. 2018;70:30–5.

18. Health Department [Ministero della Salute]. Report on the health situation in Italy, 2009–2010. [Relazione sullo stato sanitario del paese 2009–2010]. https://www.salute.gov.it/imgs/C_17_pubblicazioni_1655_allegato.pdf. Accessed 4 Feb 2022.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.